9.13.19
17 min. Read

The Pear Therapeutics Report

In this article:

In this 4,500-word report, E&O digs into the strategic moves, challenges, and successes that the Pear Therapeutics executive team has navigated since its founding five years ago. The report covers dozens of Pear’s therapeutic areas of interest; financial details from licensing agreements the company has forged with academic researchers; why it acquired a small tech startup in its early years; its failed direct-to-consumer products and more.

Fresh from vacation, ex-McKinsey analyst and then-venture capitalist Corey McCann M.D. Ph.D. stepped up to the mic at the first-ever NeuroGaming conference in 2013 and asked a question. Well, three

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
The Spring Health Report
8.18.23
20 min. Read
The Sword Health Report
8.02.23
21 min. Read
The Big Health Report
5.12.23
29 min. Read
The Virta Health Report
10.28.22
31 min. Read
Who controls the Spice?
5.27.22
25 min. Read
The Noom Report
10.29.21
39 min. Read
The Crossover Health Report
4.19.21
22 min. Read
Analysis: Livongo founders’ HAAC SPAC
1.25.21
11 min. Read
The UnitedHealth Group Report
12.30.20
30 min. Read
The Virgin Pulse Report
9.25.20
14 min. Read
  • First
  • Previous
  • 1 of 2
  • Next
  • Last